Share:

Posted by Marilyn McGoldrick on Oct 30, 2014 12:39:00 PM

janssen_logo

The Judicial Panel on MultiDistrict Litigation has been asked to certify a new MultiDistrict Litigation for the plaintiffs alleging injuries and death caused by prescription anticoagulant Xarelto. Since Xarelto was approved by the Food and Drug Administration (FDA) in 2011, doctors and patients have been reporting a number of serious side effects, including severe gastrointestinal and rectal bleeding, causing decreased hemoglobin levels requiring blood transfusions. In 2012 alone, 2,018 adverse events were recorded by the FDA’s MedWatch reporting system, including 151 deaths from uncontrolled bleeding.

Bayer_Logo.svgXarelto (generic name, rivaroxaban) is approved to prevent or treat pulmonary embolism (PE) and deep vein thrombosis (DVT). It is also prescribed to patients with atrial fibrillation to prevent strokes.Patients who have had knee or hip replacement surgery are often prescribed Xarelto to prevent the formation of blood clots. The drug is manufactured by Bayer HealthCare AG and licensed for distribution by Janssen Pharmaceuticals, Inc.

It is suspected that Xarelto leads to significant incidence of gastrointestinal and rectal bleeding that can lead to decreased hemoglobin levels requiring blood transfusions. Most serious Xarelto injuries and deaths arise from internal bleeding. Potential signs of Xarelto internal bleeding are:

  •        Prolonged bleeding from cuts
  •        Unusual swelling or bleeding
  •        Heavy or prolonged menstrual flow
  •        Frequent nose bleeds
  •        Coughing or vomiting up blood
  •        Blood in urine and/stools
  •        Unusual bruising

Xarelto is in a class of drugs called new oral anticoagulants (NOACs) which were sold as alternatives to Coumadin (warfarin) as treatments for a variety of blood clot disorders. The other drugs in the NOAC class are Pradaxa and Eliquis, and all three NOACs do not require regular blood monitoring, which is required of warfarin users. The maker of Pradaxa settled a similar class action in 2014 for $650 million dollars,

Xarelto has been heavily advertised in the media, including being the #1 product advertised in medical journals in 2013. Almost 1 million prescriptions for Xarelto were written in 2013, resulting in almost $2 billion dollars in sales.

If you or someone you love has used Xarelto and suffered serious injury resulting from internal bleeding, our Xarelto injury lawyers can help. Please call our experienced defective drug litigation attorneys at 888-341-1405 or tell us your story here for a free no obligation consultation.